Ardelyx/$ARDX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Ardelyx

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Ticker

$ARDX
Primary listing

Industry

Biotechnology

Employees

395

ISIN

US0396971071

Ardelyx Metrics

BasicAdvanced
$1.1B
-
-$0.23
0.76
-

What the Analysts think about Ardelyx

Analyst ratings (Buy, Hold, Sell) for Ardelyx stock.

Bulls say / Bears say

Ardelyx reported significant commercial progress in 2024, achieving total revenue of $333.6 million, including $319.2 million in U.S. net product sales, indicating strong market acceptance of its products. (GlobeNewswire)
The company's lead product, tenapanor, has been approved by the FDA for the treatment of chronic kidney disease, expanding its market potential and addressing a significant unmet medical need. (The Motley Fool)
Institutional investors, such as State Street Corp, have increased their holdings in Ardelyx, reflecting confidence in the company's growth prospects. (MarketBeat)
Ardelyx reported a net loss in Q1 2025, missing revenue estimates by 8.14%, which may raise concerns about its financial stability. (ChartMill)
Insider selling activity, including CEO Michael Raab's sale of 41,666 shares, might signal a lack of confidence in the company's short-term prospects. (Defense World)
Analysts have reduced their price targets for Ardelyx, with Jefferies Financial Group lowering its price objective from $11.00 to $8.00, indicating tempered expectations for future performance. (Defense World)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.

Ardelyx Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Ardelyx Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ARDX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs